%0 Journal Article
%T Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte sub-populations upon ART initiation
%A Edwin J Heeregrave
%A Mark J Geels
%A Elly Baan
%A Renee M van der Sluis
%A William A Paxton
%A Georgios Pollakis
%J AIDS Research and Therapy
%D 2010
%I BioMed Central
%R 10.1186/1742-6405-7-42
%X From five patients cellular HIV-1 infection levels were quantified before and after initiation of therapy (2-5 weeks). Through sequencing the C2V3 region of the HIV-1 gp120 envelope, we studied the effect of short-term therapy on virus variants derived from na£żve, central memory and effector memory CD4+ lymphocyte subsets.During short-term ART, HIV-1 infection levels declined in all lymphocyte subsets but not as much as RNA levels in serum. Virus diversity in the na£żve and central memory lymphocyte populations remained unchanged, whilst diversity decreased in serum and the effector memory lymphocytes. ART differentially affected the virus populations co-circulating in one individual harboring a dual HIV-1 infection. Changes in V3 charge were found in all individuals after ART initiation with increases within the effector memory subset and decreases found in the na£żve cell population.During early ART virus diversity is affected mainly in the serum and effector memory cell compartments. Differential alterations in V3 charge were observed between effector memory and na£żve populations. While certain cell populations can be targeted preferentially during early ART, some virus strains demonstrate varied sensitivity to therapy, as shown from studying two strains within a dual HIV-1 infected individual.Antiretroviral therapy (ART) has proven to be successful against human immunodeficiency virus type 1 (HIV-1) and results in undetectable plasma levels for many years. However, an increasing number of studies report on adverse events and toxicities [1,2]. Additional drawbacks to therapy are adherence and the considerable costs. In certain situations a more simplified antiretroviral regimen may be suitable, for instance as short-term use to prevent mother-to-child-transmission (MTCT), maintenance therapy after HAART or possibly as pre-exposure prophylaxis [3-7]. Despite the increased likelihood of viremia and emergence of resistance, prophylactic and/or short-term therapeutic u
%U http://www.aidsrestherapy.com/content/7/1/42